MedPath

Rapt Therapeutics' RPT193 Faces Setback in Atopic Dermatitis Development

• RAPT Therapeutics' RPT193 saw its Phase Transition Success Rate (PTSR) for atopic dermatitis decrease by 13 points to 78%, despite positive Phase Ib trial results. • The Phase Ib trial data showed a 36.3% improvement from baseline in Eczema Area and Severity Index (EASI) score with RPT193, compared to 17% with placebo over four weeks. • RPT193's Likelihood of Approval (LoA) also experienced a slight decrease of one point, settling at 3%, based on GlobalData's analysis. • Rapt Therapeutics is planning to advance RPT193 into a Phase IIb trial for atopic dermatitis, with the drug targeting CCR4 on Th2 cells.

RAPT Therapeutics' RPT193, an oral drug targeting CCR4 on Th2 cells, has experienced a setback in its development for moderate-to-severe atopic dermatitis. The drug's Phase Transition Success Rate (PTSR) decreased by 13 points to 78% following the announcement of positive topline Phase Ib trial results on June 14. The updated PTSR was reported on June 18.
The Phase Ia/Ib trial (NCT04271514) involved 21 patients treated with RPT193 and 10 patients in the placebo arm. After four weeks, RPT193 demonstrated a 36.3% improvement from baseline in the Eczema Area and Severity Index (EASI) score, while the placebo group showed a 17% improvement. The EASI score was one of the trial's efficacy endpoints. RAPT Therapeutics has expressed intentions to advance RPT193 into a Phase IIb trial for atopic dermatitis.

Impact on Approval Odds

In addition to the PTSR decrease, RPT193's Likelihood of Approval (LoA) also declined by one point to 3%. GlobalData's analysis, which uses a combination of machine learning and a proprietary algorithm, calculates LoA by compounding the PTSR at each stage the drug has yet to progress through. These metrics consider factors such as therapy area, indication, and molecule type.

RAPT's Market Position

Rapt Therapeutics currently has a market capitalization of $1.02 billion.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Clinical Trials

Related Topics

RAPT Therapeutics Initiates Phase 2a Trial of RPT193 for Moderate-to-Severe Asthma

RAPT Therapeutics has commenced a Phase 2a clinical trial to assess RPT193, an oral, once-daily monotherapy, for treating moderate-to-severe asthma.
The trial is a global, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of RPT193 over 14 weeks.

RAPT Therapeutics Advances RPT193 in Phase 2 Trial for Moderate-to-Severe Atopic Dermatitis

A new Phase 2 clinical trial is evaluating RPT193, a novel therapeutic candidate for moderate-to-severe atopic dermatitis in adults. The randomized, placebo-controlled study aims to assess both the efficacy and safety profile of this potential treatment option for a condition that affects millions globally.

MaaT Pharma Completes Enrollment in Phase 3 Trial of MaaT013 for Acute Graft-versus-Host Disease

MaaT Pharma has completed recruitment for its Phase 3 ARES trial evaluating MaaT013 in patients with steroid and ruxolitinib-refractory acute Graft-versus-Host Disease.
The ARES trial is a multicenter, European, open-label, single-arm study assessing the safety and efficacy of MaaT013, with topline results expected in January 2025.

Union Therapeutics Advances Orismilast to Phase III for Atopic Dermatitis After Positive Phase IIb Results

Union Therapeutics plans to initiate a Phase III trial for orismilast in atopic dermatitis following successful Phase IIb results.
The Phase IIb ADESOS trial demonstrated a significant reduction in eczema area and severity index (EASI) scores with orismilast.

Liraglutide Shows Promise in Pediatric Obesity, While Oncology Trials Face Setbacks

Novo Nordisk's liraglutide demonstrated a significant reduction in BMI in a Phase III trial involving children aged 6-11, showing potential for pediatric obesity treatment.
Vaxcyte's VAX-31 pneumonia vaccine showed positive Phase I/II topline data, increasing its Phase Transition Success Rate (PTSR) in streptococcal pneumonia.

Turn Therapeutics' GX-03 Shows Promise in Atopic Dermatitis by Inhibiting Key Cytokines

Turn Therapeutics' GX-03 demonstrated significant inhibition of IL-31, IL-36α, and IL-36γ in a preclinical eczema model, suggesting potential efficacy in atopic dermatitis.
The study showed a 67.7% reduction in IL-31 levels compared to placebo (p < 0.000001), highlighting GX-03's ability to modulate key cytokines involved in eczema pathogenesis.

RAPT Therapeutics Halts Zelnecirnon Trials in Atopic Dermatitis and Asthma Following FDA Clinical Hold

RAPT Therapeutics has decided to close and unblind its Phase 2b trial of zelnecirnon in atopic dermatitis and its Phase 2a trial in asthma after an FDA clinical hold.
The clinical hold was initiated due to a serious adverse event of liver failure requiring a transplant in one patient during the atopic dermatitis trial.

Ropeginterferon Alfa-2b Evaluated in Phase III Trial for Essential Thrombocythemia

The ROP-ET trial is a phase III study assessing ropeginterferon alfa-2b for essential thrombocythemia (ET) patients ineligible for or resistant/intolerant to other cytoreductive treatments.
The primary objective is to determine the disease response rate at 12 months, based on modified ELN criteria, including blood count remission and symptom improvement.

RAPT Therapeutics Announces Positive Results from Phase 1a/1b Clinical Trial of Zelnecirnon for Atopic Dermatitis

RAPT Therapeutics has published promising results from its Phase 1a/1b clinical trial of zelnecirnon (RPT193) for treating atopic dermatitis, showing significant clinical and molecular improvements with no serious adverse events reported.

RPT193 Shows Clinical Improvement in Atopic Dermatitis Patients

RPT193, an oral CCR4 antagonist, demonstrated greater improvements in clinical efficacy endpoints compared to placebo in adults with moderate to severe atopic dermatitis.
The Phase 1 study highlighted that RPT193 was well-tolerated, with most treatment-emergent adverse events being mild to moderate across all cohorts.

Reference News

[1]
Rapt’s RPT193 in atopic dermatitis drops by 13 points
clinicaltrialsarena.com · Jun 24, 2021

RAPT Therapeutics' RPT193 for atopic dermatitis saw its Phase Transition Success Rate drop to 78% despite positive Phase...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy